Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Osteosarcoma is the most common type of bone cancer in children, adolescents and young
adults. Treatment with surgery and a combination of three conventional chemotherapy drugs can
cure nearly two-thirds patients with osteosarcoma, but the treatment can also cause
irreversible damage to the kidneys and cause permanent hearing loss. The purpose of this
study is to evaluate new approaches to prevent these side effects without interfering with
the beneficial effects of the chemotherapy drugs on the cancer by using our knowledge of how
the drugs damage the kidney and cochlear hair cells in the ear to selectively block these
side effects. Preventing these side effects without interfering with the anti-cancer effect
of the drugs will improve the outcome in survivors and may also improve the effectiveness of
the chemotherapy regimen by preventing treatment delays and dose reductions that are often
caused by the side effects. Patients will be carefully monitored to ensure that the new
interventions do not adversely affect response to the treatment and do not increase the other
side effects of the chemotherapy. Specifically, we will monitor the nutritional status of the
patients closely and ask patients to complete a survey describing the side effects after each
treatment cycle. We will also collect a small sample of cancer tissue at the time of biopsy
and surgery from each patient on this study for testing to determine new classes of
anti-cancer drugs currently under development may have a role in treating osteosarcoma. If
effective, these new approaches to prevent kidney damage and hearing loss will be applicable
in other types of cancers treated with the same chemotherapy drugs.